Study on Adding Amivantamab to Standard Treatment for Recurrent or Metastatic Head and Neck Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that cannot be cured with local treatments.
  • Eligible cancer locations include the mouth, throat, and voice box.
  • Cancer must not originate from the nasopharynx or an unknown location.
  • HPV status must be known for throat cancers and must be negative.
• Must not have received systemic therapy for recurrent or metastatic cancer.
• Must be in good general health with an ECOG performance status of 0 or 1.
• Must have measurable cancer according to specific medical criteria.

Exclusion Criteria

• Have an uncontrolled illness.
• Have untreated cancer that has spread to the brain or a history of cancer in the brain's lining.
• Have a history of serious heart disease.
• Have poor organ or bone marrow function.
• Have known allergies or intolerances to any of the study drugs, including Amivantamab, Pembrolizumab, Carboplatin, Cisplatin, 5-FU, and Hyaluronidase.